ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "scleroderma and systemic sclerosis"

  • Abstract Number: 1464 • 2012 ACR/ARHP Annual Meeting

    Comparison of Baseline Characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) Cohort to Patients Enrolled in Clinical Trials of Diffuse Systemic Sclerosis

    Heather Gladue1, Daniel Furst2, Veronica Berrocal3, James R. Seibold4, Peter A. Merkel5, Maureen D. Mayes6, Kristine Phillips7, Robert W. Simms8, Shervin Assassi9, Philip J. Clements10, Paul Maranian11 and Dinesh Khanna12, 1University of Michigan, Ann Arbor, MI, 2David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, 3Div of Rheumatology, University of Michigan, Ann Arbor, MI, 4Scleroderma Research Consultants LLC, Avon, CT, 5University of Pennsylvania, Philadelphia, PA, 6Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 7Rheumatology, University of Michigan Medical School, Ann Arbor, MI, 8Rheumatology, Boston University School of Medicine, Boston, MA, 9Rheumatology, Univ of Texas Health Science Houston, Houston, TX, 10University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 11Division of Rheumatology, UCLA Medical School, Los Angeles, CA, 12Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI

    Background/Purpose: Randomized clinical trials (RCTs) of treatment of diffuse systemic sclerosis (dcSSc) would benefit from a composite index that predicted efficacy better than current standard…
  • Abstract Number: 1470 • 2012 ACR/ARHP Annual Meeting

    Clinical Features Associated with Anti-Th/to in Non-Scleroderma Patients – Sine Scleroderma?

    Ann D. Chauffe1, Minoru Satoh1, Angela Ceribelli2, Edward K.L. Chan2, Yi Li1, Eric S. Sobel3, Westley H. Reeves4 and Michael R. Bubb1, 1Medicine, University of Florida, Gainesville, FL, 2Oral Biology, University of Florida, Gainesville, FL, 3Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, 4Rheumatology & Clinical Imm, University of Florida, Gainesville, FL

    Background/Purpose: Autoantibodies in scleroderma (systemic sclerosis, SSc) such as anti-topoisomerase I (Scl-70), RNA polymerase III, centromere, U3RNP/fibrillarin, and Th/To are associated with a unique subset…
  • Abstract Number: 853 • 2012 ACR/ARHP Annual Meeting

    Systemic Sclerosis Classification Criteria: Developing Methods for Multi-Criteria Decision Analysis

    Sindhu R. Johnson1, Raymond P. Naden2, Jaap Fransen3, Frank H.J. van den Hoogen4, Janet E. Pope5, Murray Baron6, Alan G. Tyndall7, Marco Matucci-Cerinic8 and Dinesh Khanna on behalf of ACR/EULAR Classification Criteria SSc9, 1Dept of Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 2Auckland City Hospital, Auckland, New Zealand, Austria, 3Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, 5Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 6Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 7Rheumatology, University of Basel, Basel, Switzerland, 8Medicine, Univ Florence, Firenze, Italy, 9Div of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Classification criteria for systemic sclerosis (SSc) are being developed. Twenty-three candidate criteria have been identified, but need to be reduced. The objectives of this…
  • Abstract Number: 711 • 2012 ACR/ARHP Annual Meeting

    Myopathy Is a Poor Prognostic Feature in Systemic Sclerosis: Results From the Canadian Scleroderma Research Group

    MIchelle Jung1, Murray Baron2, Marie Hudson3, Ashley Bonner4, Janet E. Pope5 and Canadian Scleroderma Research Group6, 1Western University, London, ON, Canada, 2Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 3Jewish General Hospital, McGill University, Montreal, QC, Canada, 4McMaster University, Hamilton, ON, Canada, 5Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 6Montreal, QC, Canada

    Background/Purpose: Myopathy / myositis is associated with more severe systemic scleroderma (SSc).  The aim of this study was to determine such clinical information from the…
  • Abstract Number: 720 • 2012 ACR/ARHP Annual Meeting

    Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis

    Lada Miller1, Sandra Chartrand1, Martial Koenig2, Jean-Richard Goulet3, Eric Rich1, Michal Abrahamowicz4, Jean-Luc Senécal1 and Tamara Grodzicky1, 1Rheumatology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, 2Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, 3Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, 4Centre Universitaire de Santé McGill (CUSM), Montreal, QC, Canada

    Background/Purpose: Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in systemic sclerosis (SSc). Pulmonary arterial hypertension (PAH) is reportedly the most frequent…
  • Abstract Number: 721 • 2012 ACR/ARHP Annual Meeting

    Measurement of Pulmonary Arteries by Cardiac Magnetic Resonance Imaging: A Simple and Useful Tool for the Detection of Pulmonary Hypertension in Systemic Sclerosis Patients without Overt Cardiac Microvascular Perfusion Defects or Fibrosis

    Sandra Chartrand1, Lada Miller1, Martial Koenig2, Jean-Richard Goulet1, Eric Rich1, Anne S. Chin3, Yves Provost3, Carl Chartrand-Lefebvre3, Pauline Gou1, Jean-Luc Senécal1 and Tamara Grodzicky1, 1Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, 2Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, 3Radiology, Hôtel-Dieu de Montréal du CHUM, Montréal, QC, Canada

    Background/Purpose: Pulmonary hypertension (PH) is a major complication of systemic sclerosis (SSc). We observed that a significant proportion of our SSc patients with PH as…
  • Abstract Number: 710 • 2012 ACR/ARHP Annual Meeting

    Optical Density Measure of the Papillary Dermis Discriminates As Abnormal Clinically Uninvolved Skin in Systemic Sclerosis and Correlates with Severity of Skin Thickness

    Giuseppina Abignano1, Sibel Z. Aydin2, Concepcion Castillo-Gallego3, Daniel Woods4, Adam Meekings5, Dennis McGonagle6, Paul Emery7 and Francesco Del Galdo8, 1Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, 2Unit of Rheumatology, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, 3Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 4Michelson Diagnostics Ltd, Kent, United Kingdom, 5Michelson Diagnostics Ltd, Kent, United Kingdom, Kent, United Kingdom, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 7Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, 8Musculoskeletal Diseases, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom

    Background/Purpose: Skin involvement in systemic sclerosis (SSc) is often primary outcome in clinical trials and its severity inversely correlates with prognosis. Nevertheless, an objective quantitative…
  • Abstract Number: 92 • 2012 ACR/ARHP Annual Meeting

    Combined Response Index in Diffuse Systemic Sclerosis (CRISS)—Which External Anchors to Use When Developing the Index? Baseline Analysis

    Dinesh Khanna1, Veronica Berrocal2, James R. Seibold3, Peter A. Merkel4, Maureen D. Mayes5, Kristine Phillips6, Robert W. Simms7, Shervin Assassi5, Philip J. Clements8 and Daniel Furst9, 1Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 2Div of Rheumatology, University of Michigan, Ann Arbor, MI, 3Scleroderma Research Consultants LLC, Avon, CT, 4University of Pennsylvania, Philadelphia, PA, 5Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 6Rheumatology, University of Michigan, Ann Arbor, MI, 7Rheumatology, Boston University School of Medicine, Boston, MA, 8University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 9Div of Rheumatology, UCLA Medical School, Los Angeles, CA

     Background/Purpose: As part of an NIH sponsored effort to develop a data-driven CRISS, we evaluated the face, content, and construct validity (convergent and discriminant) of…
  • Abstract Number: L3 • 2012 ACR/ARHP Annual Meeting

    Classification Criteria for Systemic Sclerosis: Preliminary Results

    Janet E. Pope1, Dinesh Khanna2, Jaap Fransen3, Sindhu R. Johnson4, Murray Baron5, Alan G. Tyndall6, Marco Matucci-Cerinic7, Raymond P. Naden8, Frank H.J. van den Hoogen9 and ACR/EULAR Classification Criteria for Systemic Sclerosis10, 1Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 2Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 3Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada, 5Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 6Rheumatology, University of Basel, Basel, Switzerland, 7Department of Biomedicine & Division of Rheumatology AOUC, University of Florence, Florence, Italy, 8Auckland City Hospital, Auckland, New Zealand, Austria, 9Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, 10Janet Pope, London, ON, Canada

    Background/Purpose: The existing 1980 classification criteria for systemic sclerosis (SSc) are suboptimal for patients with early SSc and some patients with limited cutaneous SSc (lcSSc)…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology